Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Sponsor
Abbott
Study ID
NCT00646178
Phase
PHASE3
Status
Completed

Conditions

  • Arthritis
  • Psoriatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy

Key Dates

Start date
Jun 30, 2003
Status verified
Mar 2008
Primary completion
Mar 31, 2004

Study Design

Enrollment
102 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: A
  • Placebo Comparator: B

Primary Outcome Measure

ACR20 [ Time Frame: Week 12 ]

Related Studies